FP
KDNY

Foundry Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Foundry Partners’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-33,836
Closed -$673K – 407
2019
Q1 		$673K Buy
33,836
+9,079
+37% +$158K 0.03% 334
2018
Q4 		$327K Buy
24,757
+3,376
+16% +$67.4K 0.01% 359
2018
Q3 		$786K Sell
21,381
-34
-0.2% -$1.09K 0.03% 336
2018
Q2 		$750K Sell
21,415
-1,391
-6% -$53.3K 0.03% 333
2018
Q1 		$1.06M Buy
22,806
+5,446
+31% +$199K 0.05% 322
2017
Q4 		$651K Sell
17,360
-4,789
-22% -$209K 0.03% 329
2017
Q3 		$1.18M Sell
22,149
-64
-0.3% -$3.8K 0.05% 315
2017
Q2 		$1.27M Sell
22,213
-502
-2% -$25.2K 0.05% 324
2017
Q1 		$1.22M Buy
22,715
+7,225
+47% +$408K 0.05% 336
2016
Q4 		$883K Buy
+15,490
New +$937K 0.04% 353

Other funds holding KDNY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Foundry Partners's KDNY Position: Q2 2019 in Review

Foundry Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2019, closing a stake of 33,836 shares — an estimated $673K sold.

Foundry Partners first reported a position in KDNY in Q4 2016 and held it in 10 quarters. The position peaked at $1.27M in Q2 2017. 97 funds tracked by Wall St. Rank hold KDNY as of Q2 2019.

  • Foundry Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Foundry Partners sold 33,836 Chinook Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $673K.
  • Foundry Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2016 and held it in 10 quarters.
  • Foundry Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $1.27M in Q2 2017.
  • 97 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Foundry Partners's 13F filing for Q2 2019, filed 18 Jul 2019.